Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.32 |
| ▸ | HTR3B | O95264 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.32 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18086469 | 0.82 | P2RX7 (0.36) | LMNAIDO1PYCR1MEN1ALDH1A1 | |
| SCHEMBL21446974 | 0.81 | IDO1 (0.39) | IDO1KLKB1HTR3EHTR3BHTR3A | |
| SCHEMBL2922519 | 0.81 | IDO1 (0.35) | IDO1KLKB1HTR3EHTR3BHTR3A | |
| SCHEMBL21139129 | 0.80 | PDE2A (0.33) | LMNAIDO1KLKB1PYCR1PDE2A | |
| SCHEMBL16941876 | 0.79 | TAAR1 (0.34) | MEN1ALDH1A1KMT2APTGS1PTGS2 | |
| SCHEMBL21733550 | 0.78 | FFAR4 (0.36) | IDO1PDE2A | |
| SCHEMBL16942323 | 0.78 | P2RX7 (0.37) | LMNAIDO1PYCR1MEN1ALDH1A1 | |
| SCHEMBL10290476 | 0.75 | MPO (0.40) | MEN1ALDH1A1KMT2A | |
| SCHEMBL16939396 | 0.74 | P2RX7 (0.41) | PYCR1S1PR1PTGS2CTSSCTSK | |
| SCHEMBL23879465 | 0.74 | GPR17 (0.51) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043959-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2023-02-09 | — | — | US | disclosed |
| US-20190300526-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2019-10-03 | — | — | US | disclosed |
| US-10336754-B2 | Pyrimidinones as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-02 | — | — | US | disclosed |
| US-10287288-B2 | Factor XIa macrocyclic inhibitors bearing alkyl or cycloalkyl P2' moieties | BRISTOL-MYERS SQUIBB (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180186795-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2018-07-05 | — | — | US | disclosed |
| US-20180162821-A1 | FACTOR XIA MACROCYCLES WITH NOVEL P1 GROUPS | BRISTOL-MYERS SQUIBB COMPANY | 2018-06-14 | — | — | US | disclosed |
| WO-2013056060-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-18 | — | — | WO | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | LMNA 3446/4885IDO1 107/4885KLKB1 4701/4885 |
| US-20180186795-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F2 | LMNA 1886/4885IDO1 835/4885KLKB1 7/4885 |
| US-20190300526-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | C5AR2, C5AR1, C3AR1 | LMNA 2103/4885IDO1 573/4885KLKB1 1422/4885 |
| US-20180162821-A1 | FACTOR XIA MACROCYCLES WITH NOVEL P1 GROUPS | F11, F12, TFPI | LMNA 450/4885IDO1 3133/4885KLKB1 17/4885 |
| US-20230043959-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | LMNA 4686/4885IDO1 62/4885KLKB1 2154/4885 |
| US-10287288-B2 | Factor XIa macrocyclic inhibitors bearing alkyl or cycloalkyl P2' moieties | TFPI, TFPI2, F11 | LMNA 1801/4885IDO1 2581/4885KLKB1 14/4885 |
| US-10336754-B2 | Pyrimidinones as factor XIa inhibitors | TFPI, TFPI2, F2 | LMNA 1886/4885IDO1 835/4885KLKB1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.